Journal
BMJ OPEN
Volume 9, Issue 8, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2018-027940
Keywords
anti-tuberculosis drug-induced liver injury; genetic polymorphisms; meta-analysis; drug-metabolizing enzyme; drug transporter; tuberculosis
Categories
Funding
- Research Resettlement Fund for the new faculty of Seoul National University
Ask authors/readers for more resources
Objectives The objective of this study was to investigate the association between genetic polymorphisms of N-acetyltransferase 2 (NAT2), cytochrome P450 2E1 (CYP2E1), glutathione S-transferase (GST) and solute carrier organic anion transporter family member 1B1 (SLCO1B1) and the risk of anti-tuberculosis drug-induced liver injury (ATDILI). Design Systematic review and meta-analysis. Data sources PubMed, Embase, Web of Science and Cochrane Reviews databases were searched through April 2019. Eligibility criteria We included case-control or cohort studies investigating an association between NAT2, CYP2E1, GST or SLCO1B1 polymorphisms and the ATDILI risk in patients with tuberculosis. Data extraction and synthesis Three authors screened articles, extracted data and assessed study quality. The strength of association was evaluated for each gene using the pooled OR with a 95% CI based on the fixed-effects or random-effects model. Sensitivity analysis was performed to confirm the reliability and robustness of the results. Results Fifty-four studies were included in this analysis (n=26 for CYP2E1, n=35 for NAT2, n=19 for GST, n=4 for SLCO1B1). The risk of ATDILI was significantly increased with the following genotypes: CYP2E1 RsaI/PstI c1/c1 (OR=1.39, 95%CI 1.06 to 1.83), NAT2 slow acetylator (OR=3.30, 95%CI 2.65 to 4.11) and GSTM1 null (OR=1.30, 95%CI 1.12 to 1.52). No significant association with ATDILI was found for the genetic polymorphisms of CYP2E1 DraI, GSTT1, GSTM1/GSTT1, SLCO1B1 388A>G and SLCO1B1 521T>C (p>0.05). Conclusions ATDILI is more likely to occur in patients with NAT2 slow acetylator genotype, CYP2E1 RsaI/PstI c1/c1 genotype and GSTM1 null genotype. Close monitoring may be warranted for patients with these genotypes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available